{"id":390902,"date":"2017-09-22T00:00:00","date_gmt":"2017-09-22T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/paprim0001-2017-biopharma-rheumatoid-arthritis-patient-profiler-us-2017\/"},"modified":"2026-04-14T10:27:26","modified_gmt":"2026-04-14T10:27:26","slug":"paprim0001-2017-biopharma-rheumatoid-arthritis-patient-profiler-us-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/paprim0001-2017-biopharma-rheumatoid-arthritis-patient-profiler-us-2017\/","title":{"rendered":"Rheumatoid Arthritis | Patient Profiler | US | 2017"},"content":{"rendered":"<p>Rheumatoid arthritis (<abbr title=\"rheumatoid arthritis\">RA<\/abbr>) treatment is typically initiated with cost-effective conventional <abbr title=\"disease-modifying antirheumatic drug\">DMARD<\/abbr>s, such as methotrexate. The U.S. market for conventional <abbr title=\"disease-modifying antirheumatic drug\">DMARD<\/abbr>-refractory <abbr title=\"rheumatoid arthritis\">RA<\/abbr> patients is crowded with efficacious biologics, including blockbuster tumor necrosis factor alpha (<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-alpha) inhibitors Amgen\u2019s Enbrel, AbbVie\u2019s Humira, and Janssen\u2019s Remicade, as well as non-<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-alpha inhibitors such as Bristol-Myers Squibb\u2019s Orencia, Roche\u2019s\/Genentech\u2019s Rituxan and Actemra. In addition, Pfizer\u2019s <abbr title=\"Janus activated kinase\">Jak<\/abbr> inhibitor Xeljanz, the first targeted oral molecule approved for <abbr title=\"rheumatoid arthritis\">RA<\/abbr>, has been approved for almost five years in the United States and is gaining steady uptake. The <abbr title=\"rheumatoid arthritis\">RA<\/abbr> market is expected to become increasingly competitive, with upcoming approvals of additional agents and the entry of biosimilars, making brand differentiation and understanding of key patient characteristics ever more critical for marketers.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What is the patient share in <abbr title=\"rheumatoid arthritis\">RA<\/abbr> for <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-alpha inhibitors and other key segments?<\/li>\n<li>What are the demographic characteristics and clinical profiles of <abbr title=\"rheumatoid arthritis\">RA<\/abbr> patients on biologics and Xeljanz?<\/li>\n<li>What are the key risk factors, comorbidities, and co-prescribed\/additional therapies by patient segment for <abbr title=\"rheumatoid arthritis\">RA<\/abbr>?<\/li>\n<li>\u00a0How do <abbr title=\"rheumatoid arthritis\">RA<\/abbr> patient cohorts compare in care utilization and outcomes (physician visits and other healthcare encounters)?<\/li>\n<li>What are the reimbursed and out-of-pocket costs?<\/li>\n<li>What insurance type do <abbr title=\"rheumatoid arthritis\">RA<\/abbr> patients have?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Patient Profiler provides disease-specific, patient-level analysis of key demographic, clinical, and cost-based metrics underlying brand use, all sourced with <abbr title=\"Decision Resources Group\">DRG<\/abbr>\u2019s comprehensive Real World Data (<abbr title=\"real-world data\">RWD<\/abbr>) repository.<\/p>\n","protected":false},"template":"","class_list":["post-390902","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatoid-arthritis","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390902","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390902\/revisions"}],"predecessor-version":[{"id":394026,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390902\/revisions\/394026"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390902"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}